Practices for RhD alloimmunization prevention: a vignette-based survey of midwives

References

• American College of Obstetricians and Gynecologists. Practice Bulletin No. 181: Prevention of Rh D Alloimmunization. Obstet Gynecol. Août. 2017;130(2):e57–70.
   PubMed Web of Science ®Google Scholar
• Zipursky A, Paul VK. The global burden of Rh disease. Arch Dis Child Fetal Neonatal Ed. 2011;96(2):F84–85.
   PubMed Web of Science ®Google Scholar
• Branger B, Winer N. [Epidemiology of anti-D allo-immunization during pregnancy. J Gynecol Obstet Biol Reprod (Paris). Févr. 2006;35(1 Suppl):1S87–81S92.
   PubMedGoogle Scholar
• Flegr J. Heterozygote advantage probably maintains rhesus factor blood group polymorphism: ecological regression study. PLoS One. 2016;11(1):e0147955.
   PubMed Web of Science ®Google Scholar
• Erikstein BS, Hagen KG, Hervig T. RBC alloantibody prevalence and specificity in a Western Norwegian tertiary hospital. Transfus Med. 2019;29(3):169–178.
   PubMed Web of Science ®Google Scholar
• Smith HM, Shirey RS, Thoman SK, et al. Prevalence of clinically significant red blood cell alloantibodies in pregnant women at a large tertiary-care facility. Immunohematology. 2019;29(4):127–130.
   Google Scholar
• Slootweg YM, Koelewijn JM, van Kamp IL, et al. Third trimester screening for alloimmunisation in Rhc-negative pregnant women: evaluation of the Dutch national screening programme. BJOG. 2016;123(6):955–963.
   PubMed Web of Science ®Google Scholar
• Dajak S, Stefanović V, Capkun V. Severe hemolytic disease of fetus and newborn caused by red blood cell antibodies undetected at first-trimester screening (CME). Transfusion (Paris). 2011;51(7):1380–1388.
   Web of Science ®Google Scholar
• Bhutani VK, Zipursky A, Blencowe H, et al. Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatr Res. 2013;74(Suppl 1):86–100.
   PubMedGoogle Scholar
• Liumbruno GM, D'Alessandro A, Rea F, et al. The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation. Blood Transfus. 2010;8(1):8–16.
   PubMed Web of Science ®Google Scholar
• de Haas M, Finning K, Massey E, et al. Anti-D prophylaxis: past, present and future. Transfus Med. 2014;24(1):1–7.
   PubMed Web of Science ®Google Scholar
• Bowman J. Thirty-five years of Rh prophylaxis. Transfusion (Paris). 2003;43(12):1661–1666.
   PubMed Web of Science ®Google Scholar
• McBain RD, Crowther CA, Middleton P. Anti-D administration in pregnancy for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev. 2015;(9):CD000020.DOI:10.1002/14651858.CD000020.pub2
   PubMed Web of Science ®Google Scholar
• Vivanti A, Benachi A, Huchet F-X, et al. Diagnostic accuracy of fetal rhesus D genotyping using cell-free fetal DNA during the first trimester of pregnancy. Am J Obstet Gynecol. 2016;215(5):606.e1–e5.
   PubMed Web of Science ®Google Scholar
• Moise KJ, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol. 2012;120(5):1132–1139.
   PubMed Web of Science ®Google Scholar
• Qureshi H, Massey E, Kirwan D, British Society for Haematology, et al. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med. 2014;24(1):8–20.
   PubMed Web of Science ®Google Scholar
• Collège National des Gynécologues et Obstétriciens Français. Prévention de l’allo-immunisation rhésus-D foeto-maternelle. Recommandations Pour la Pratique Clinique. 2005;18.
   Google Scholar
• Visser GHA, Thommesen T, Di Renzo GC, FIGO Committee for Safe Motherhood, Newborn Health, et al. FIGO/ICM guidelines for preventing Rhesus disease: A call to action. Int J Gynaecol Obstet. 2021;152(2):144–147.. Feb
   PubMed Web of Science ®Google Scholar
• Sperling J, Dahlke J, Sutton D, et al. Prevention of RhD alloimmunization: a comparison of four national guidelines. Amer J Perinatol. 2018;35(02):110–119.
   PubMedGoogle Scholar
• Visser GHA, Di Renzo GC, Spitalnik SL, FIGO Committee Safe Motherhood and Newborn Health. The continuing burden of Rh disease 50 years after the introduction of anti-Rh(D) immunoglobin prophylaxis: call to action. Am J Obstet Gynecol. 2019;221(3):227.e1–e4.
   PubMed Web of Science ®Google Scholar
• Bollason G, Hjartardottir H, Jonsson T, et al. Red blood cell alloimmunization in pregnancy during the years 1996-2015 in Iceland: a nation-wide population study. Transfusion (Paris). 2017;57(11):2578–2585.
   Web of Science ®Google Scholar
• Badami KG, Parker J, Kenny A, et al. Incidence of maternal sensitisation to Rh(D) in Christchurch, New Zealand and reasons for prophylaxis failures. N Z Med J. 24 Janv. 2014;127(1388):40–46.
   PubMedGoogle Scholar
• Rousseau A, Azria E, Baumann S, et al. Do obstetricians apply the national guidelines? A vignette-based study assessing practices for the prevention of preterm birth. BJOG. 2020;127(4):467–476.
   PubMed Web of Science ®Google Scholar
• Rousseau A, Rozenberg P, Perrodeau E, et al. Variations in postpartum hemorrhage management among midwives: a national vignette-based study. PLoS One. 2016;11(4):e0152863.
   PubMed Web of Science ®Google Scholar
• Bienenfeld S, Rodriguez-Riesco LG, Heyborne KD. Avoiding inadequate intrapartum antibiotic prophylaxis for group B Streptococci. Obstet Gynecol. 2016;128(3):598–603.
   PubMed Web of Science ®Google Scholar
• Peabody JW, Luck J, Glassman P, et al. Measuring the quality of physician practice by using clinical vignettes: a prospective validation study. Ann Intern Med. 2004;141(10):771–780.
   PubMed Web of Science ®Google Scholar
• Veloski J, Tai S, Evans AS, et al. Clinical vignette-based surveys: a tool for assessing physician practice variation. Am J Med Qual. 2005;20(3):151–157.
   PubMed Web of Science ®Google Scholar
• Peabody JW, Luck J, Glassman P, et al. Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality. JAMA. 5 avr 2000;283(13):1715–1722.
   PubMed Web of Science ®Google Scholar
• Turner RM, Lloyd-Jones M, Anumba DOC, et al. Routine antenatal anti-D prophylaxis in women who are Rh(D) negative: meta-analyses adjusted for differences in study design and quality. PLoS One. 2012;7(2):e30711.
   PubMed Web of Science ®Google Scholar
• Koby L, Grunbaum A, Benjamin A, et al. Anti-D in Rh(D)-negative pregnant women: are at-risk pregnancies and deliveries receiving appropriate prophylaxis? J Obstet Gynaecol Can Mai 2012;34(5):429–435.
   PubMedGoogle Scholar
• MacKenzie IZ, Findlay J, Thompson K, et al. Compliance with routine antenatal rhesus D prophylaxis and the impact on sensitisations: observations over 14 years. BJOG: Int J O&G. 2006;113(7):839–843.
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PHB, Davies T, Poles D, et al. Errors in anti-D immunoglobulin administration: retrospective analysis of 15 years of reports to the UK confidential haemovigilance scheme. BJOG. 2013;120(7):873–878.
   PubMed Web of Science ®Google Scholar
• Okwundu CI, Afolabi BB. Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy. Cochrane Database Syst Rev. 2013;(1):CD007885.
   PubMed Web of Science ®Google Scholar
• Viaris de Lesegno B, Beucher G, Lamendour N, et al. [Continuous medical evaluation of the prevention of fetomaternal rhesus-D allo-immunization]. J Gynecol Obstet Biol Reprod (Paris). 2013;42(4):359–365.
   PubMedGoogle Scholar
• Fyfe TM, Lavoie JG, Payne GW, et al. Rhesus D factor (RhD) negative women’s experiences with pregnancy: An interpretive description. Women Birth J Aust Coll Midwives. 2020;3(6):e511–e518.
   Google Scholar
• Oxenford K, Silcock C, Hill M, et al. Routine testing of fetal Rhesus D status in Rhesus D negative women using cell-free fetal DNA: an investigation into the preferences and information needs of women. Prenat Diagn. 2013;33(7):688–694.
   PubMed Web of Science ®Google Scholar